The Effect of SAAE on Ventricular Remodeling in PA Patients

Launched by SECOND AFFILIATED HOSPITAL OF NANCHANG UNIVERSITY · Aug 12, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a procedure called superselective adrenal arterial embolization on heart changes in patients with primary aldosteronism, a condition that affects hormone levels and can lead to high blood pressure. Researchers want to see how this procedure compares to a common medication called spironolactone in helping to improve heart health. The study is currently looking for participants aged 18 to 60 who have high blood pressure and have been diagnosed with primary aldosteronism.

To be eligible for the trial, participants must meet several criteria, including having specific blood pressure levels and being willing to undergo either the embolization procedure or continue with medication. People who are pregnant, have certain serious health conditions, or are currently involved in other clinical studies may not qualify. If you join the study, you’ll have the chance to contribute to important research that could help improve treatment options for others with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) Age 18-60 years old, regardless of gender;
• • (2) Blood pressure conditions meet one of the following: 1) Office blood pressure ≥ 140/90mmHg; 2) Ambulatory blood pressure monitoring whole day blood pressure \> 130/80 mmHg or daytime blood pressure \> 135/85 mmHg;
• • (3) After strict drug elution, it met the diagnostic criteria of primary aldosteronism, and bilateral primary aldosteronism was confirmed by adrenal venous sampling;
• • (4) No surgical intent or contraindication to surgery and willing to undergo pharmacological treatment or percutaneous superselective adrenal artery embolization;
• • (5) The patient or his/her legal representative shall sign the written informed consent approved by the ethics committee before the screening.
• Exclusion Criteria:
• • (1) Primary hypertension or secondary hypertension with other causes;
• • (2) A woman who is pregnant or lactating, or has a birth plan for the next year;
• • (3) There are serious organic diseases, especially liver and kidney dysfunction(eGFR\<45 mL/min/1.73 m2);
• • (4) Severe allergy to contrast medium;
• • (5) Other serious organic diseases, life expectancy \< 12 months;
• • (6) Adrenal CT showed adenoma.;
• • (7) Patients are enrolled or want to participate in other clinical studies. During the enrollment study, the results of this study will be affected.